2026-09-21T14:47:24Zhttps://wakespace.lib.wfu.edu/server/oai/request

oai:null:10339/571452026-09-02T17:04:52Zcom_10339_14934col_10339_38132

Alexander, Peter M. 2015-06-23T08:35:52Z 2017-06-22T08:30:09Z 2015 https://wakespace.lib.wfu.edu/handle/10339/57145 Acute leukemias are cancers of the blood and bone marrow that affect thousands of Americans annually. These diseases can be myeloid or lymphoid in origin. Common components of therapy for both types of disease involve cytarabine and an anthracycline. After initially responding to treatment, most patients eventually relapse with disease that is resistant to conventional modalities. There is a pressing need for novel therapeutic agents to treat the acute leukemias, especially in the relapsed setting. en Wake Forest University Chemoresistance Gemcitabine Leukemia Lipid conjugate THE NOVEL GEMCITABINE PHOSPHOLIPID CONJUGATE KPC34 HAS ACTIVITY AGAINST MULTIPLE MODELS OF RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA Dissertation Pardee, Timothy S Gmeiner, William H Kucera, Gregory L Marini, Frank C Wadas, Thaddeus J Cancer Biology 2017-06-22 open.access